籽粒苋在养猪生产中的应用

籽粒苋是优良而高产的饲料作物,幼嫩的茎叶鲜美可口,成熟的秸秆、籽实经青贮后质地柔软,带有酸香味,既能增强饲料的适口性又能节省一部分精料,是发展节粮型畜牧业很有前景的青饲料。下面就我场多年应用籽粒苋喂猪的实践谈谈体会。1饲喂方式青刈:我国北方一般在5月上旬种植,7月上旬待株高达60～80厘米时就可进行第—次刈割,残茬保留2～5片叶,经半个月左右,进行第二次刈割,到种子成熟期可刈割3次。割下来的籽粒苋用打浆机加水打成泥状,拌入生干料即可饲喂。青贮:青贮原理主要是利用乳酸菌通过厌氧呼吸过程,将青贮原料中的碳水化合物变成以乳酸…     

蓝绿藻与池塘养殖

在夏季,蓝绿藻是淡水养殖池塘的主要浮游植物,常因繁殖过盛形成“水华”,大量消耗池水中的溶解氧、使氮循环失调而产生毒性氨和降低水中的光照度等,造成鱼类死亡,给养殖生产带来经济损失。本文详细探讨了蓝绿藻的毒力、饵料价值、影响蓝绿藻丰度的因子、蓝绿藻对池塘环境的影响以及控制蓝绿藻的方法与技术。     

可移动式孵化水糟用生物过滤系统

人们利用生物过滤系统进行水体过滤，并重复用于人工孵化和水产研究的兴趣正日益增大。生物过滤是利用细菌除去氨和亚硝酸盐，使水：体能够再利用。因此，可以降低生产和实验研究等对水资源的利用量。利用生物过滤也能控制水温与盐度，因此，水再利用系统在河口及海洋动物的养殖中也有一定的应用价值。     

鲤鱼养殖水槽中的磷酸酶活性

天然水体的溶解无机磷与水体初级生产力有着密切关系。如果溶解无机磷含量低于限制水域初级生产力的水平，就会刺激磷酸酶的含量升高(Befman，1970等)。磷酸酶可分为由细胞膜产生的碱性磷酸酶和细胞内溶体产生的酸性磷酸酶两种，它们均能水解溶解有机体所含有的磷酸单脂，使之成为溶解无机磷而满足藻类代谢磷的生理需求(Boavida与Heath，1984等)。     

曲阜市禁烧秸秆有高招

为彻底杜绝焚烧秸秆,营造一个良好的旅游环境,曲阜市政府突出重点,强化措施,紧紧围绕秸秆液化、饲料青贮、机械还田等方法为秸秆利用寻找出路。 为保证禁烧工作的顺利开展,市政府重点采取     

长期实验的设备工作状态廉价监测系统

长期研究鱼类生长时,常需投入大量劳力、设备及其它物资,因而费用颇高。随着相关实验设备的使用置增加和实验期的延长(尤其是长期的环境模拟研究),造成高投资科学研究失败的风险会大大增加。为此,作者设计了一个可以监控,进行长期毒性研究的实验设备工作状态的系统,从而可大大降低设备在自动工作期间因功能障碍而造成实验失败的危险性。     

鱼类抗病能力的差异

本文根据国外部分研究结果,阐述了鱼类种间、种群内以及不同种群间抗病力的差异。介绍了关于鱼类抗病力的研究现状和通过遗传改良育种提高鱼类抗病力的途径。     

一种更加适合林木的灌溉技术--根区导灌技术

新疆是一个干旱的地区,生态系统非常脆弱。为了保护和改善我们的生活环境,各级政府和相关部门一直在加大植树造林的力度。随着造林面积的增加,林木灌溉的问题就更加突出,其主要表现在灌溉用水与灌溉方式上。传统的灌溉方式灌溉水利用率低,浪费严重,而滴灌等灌溉技术又存在抗堵塞和抗破坏能力差的缺点。"根区导灌技术"的出现可以从根本上解决这一问题。     

Proposed criteria for classification of acute myeloid leukemia in dogs and cats

Blood and bone marrow smears from 49 dogs and cats, believed to have myeloproliferative disorders (MPD), were examined by a panel of 10 clinical pathologists to develop proposals for classification of acute myeloid leukemia (AML) in these species. French-American-British (FAB) group and National Cancer Institute (NCI) workshop definitions and criteria developed for classification of AML in humans were adapted. Major modifications entailed revision of definitions of blast cells as applied to the dog and cat, broadening the scope of leukemia classification, and making provisions for differentiating erythremic myelosis and undifferentiated MPD. A consensus cytomorphologic diagnosis was reached in 39 (79.6%) cases comprising 26 of AML, 10 of myelodysplastic syndrome (MDS), and 3 of acute lymphoblastic leukemia (ALL). Diagnostic concordance for these diseases varied from 60 to 81% (mean 73.3 +/- 7.1%) and interobserver agreement ranged from 51.3 to 84.6% (mean 73.1 +/- 9.3%). Various subtypes of AML identified included Ml, M2, M4, M5a, M5b, and M6. Acute undifferentiated leukemia (AUL) was recognized as a specific entity. M3 was not encountered, but this subclass was retained as a diagnostic possibility. The designations M6Er and MDS-Er were introduced where the suffix "Er" indicated preponderance of erythroid component. Chief hematologic abnormalities included circulating blast cells in 98% of the cases, with 36.7% cases having >30% blast cells, and thrombocytopenia and anemia in approximately 86 to 88% of the cases. Bone marrow examination revealed panmyeloid dysplastic changes, particularly variable numbers of megaloblastoid rubriblasts and rubricytes in all AML subtypes and increased numbers of eosinophils in MDS. Cytochemical patterns of neutrophilic markers were evident in most cases of Ml and M2, while monocytic markers were primarily seen in M5a and M5b cases. It is proposed that well-prepared, Romanowsky-stained blood and bone marrow smears should be examined to determine blast cell types and percentages for cytomorphologic diagnosis of AML. Carefully selected areas of stained films presenting adequate cellular details should be used to count a minimum of 200 cells. In cases with borderline diagnosis, at least 500 cells should be counted. The identity of blast cells should be ascertained using appropriate cytochemical markers of neutrophilic, monocytic, and megakaryocytic differentiation. A blast cell count of > 30% in blood and/or bone marrow indicates AML or AUL, while a count of < 30% blasts in bone marrow suggests MDS, chronic myeloid leukemias, or even a leukemoid reaction. Myeloblasts, monoblasts, and megakaryoblasts comprise the blast cell count. The FAB approach with additional criteria should be used to distinguish AUL and various subtypes of AML (Ml to M7 and M6Er) and to differentiate MDS, MDS-ER, chronic myeloid leukemias, and leukemoid reaction. Bone marrow core biopsy and electron microscopy may be required to confirm the specific diagnosis. Immunophenotyping with lineage specific antibodies is in its infancy in veterinary medicine. Development of this technique is encouraged to establish an undisputed identity of blast cells. Validity of the proposed criteria needs to be substantiated in large prospective and retrospective studies. Similarly, clinical relevance of cytomorphologic, cytochemical, and immunophenotypic characterizations of AML in dogs and cats remains to be determined.